Free Trial

Pfizer (PFE) Stock Forecast & Price Target

$29.71
0.00 (0.00%)
(As of 10:28 AM ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 13 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 8 have given a hold rating, and 5 have given a buy rating for PFE.

Consensus Price Target

$34.50
16.12% Upside
High Forecast$45.00
Average Forecast$34.50
Low Forecast$27.00

According to the 13 analysts' twelve-month price targets for Pfizer, the average price target is $34.50. The highest price target for PFE is $45.00, while the lowest price target for PFE is $27.00. The average price target represents a forecasted upside of 16.12% from the current price of $29.71.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
11 Hold rating(s)
11 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.50$35.86$36.88$46.00
Forecasted Upside16.12% Upside18.70% Upside15.96% Upside12.26% Upside
Get Pfizer Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.12% Upside1,353.99% Upside9.10% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Barclays
2 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00+5.82%
7/10/2024Cantor Fitzgerald
3 of 5 stars
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00+59.97%
5/2/2024Morgan Stanley
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00+4.28%
5/2/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00+30.62%
3/22/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/23/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$36.00+30.67%
1/4/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$32.00+7.67%
12/14/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$42.00 ➝ $36.00+37.35%
12/14/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$34.00 ➝ $27.00+2.27%
10/16/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$42.00 ➝ $35.00+3.80%
10/16/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$36.00 ➝ $34.00+0.71%
10/16/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $35.00+9.00%
10/16/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$38.00 ➝ $39.00+21.46%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+38.66%
6/29/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$47.00 ➝ $40.00+10.22%
5/11/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$38.00-0.78%
4/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$50.00 ➝ $45.00+12.92%
2/7/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kerry Holford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$40.00-8.24%
2/1/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Perform$49.00 ➝ $48.00+8.70%
2/1/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$50.00 ➝ $46.00+4.17%
12/13/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$47.00 ➝ $60.00+15.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:45 AM ET.

PFE Forecast - Frequently Asked Questions

What is Pfizer's forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $34.50, with a high forecast of $45.00 and a low forecast of $27.00.

Should I buy or sell Pfizer stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.

Does Pfizer's stock price have much upside?

According to analysts, Pfizer's stock has a predicted upside of 17.14% based on their 12-month stock forecasts.

What analysts cover Pfizer?

Pfizer has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, and Morgan Stanley in the past 90 days.

Do Wall Street analysts like Pfizer more than its competitors?

Analysts like Pfizer less than other "medical" companies. The consensus rating for Pfizer is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PFE compares to other companies.


This page (NYSE:PFE) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners